{
    "protocolSection": {
        "identificationModule": {
            "nctId": "NCT00830167",
            "orgStudyIdInfo": {
                "id": "A0081208"
            },
            "organization": {
                "fullName": "Pfizer",
                "class": "INDUSTRY"
            },
            "briefTitle": "Randomized, Double-Blind, Placebo-Controlled Study Of Pregabalin In Patients With Fibromyalgia",
            "officialTitle": "Randomized, Double-Blind, Multicenter, Placebo-Controlled Study To Evaluate Efficacy And Safety Of Pregabalin（CI-1008）In The Treatment Of Fibromyalgia"
        },
        "statusModule": {
            "statusVerifiedDate": "2012-04",
            "overallStatus": "COMPLETED",
            "expandedAccessInfo": {
                "hasExpandedAccess": false
            },
            "startDateStruct": {
                "date": "2009-03"
            },
            "primaryCompletionDateStruct": {
                "date": "2011-05",
                "type": "ACTUAL"
            },
            "completionDateStruct": {
                "date": "2011-05",
                "type": "ACTUAL"
            },
            "studyFirstSubmitDate": "2009-01-26",
            "studyFirstSubmitQcDate": "2009-01-26",
            "studyFirstPostDateStruct": {
                "date": "2009-01-27",
                "type": "ESTIMATED"
            },
            "resultsFirstSubmitDate": "2012-04-30",
            "resultsFirstSubmitQcDate": "2012-04-30",
            "resultsFirstPostDateStruct": {
                "date": "2012-06-01",
                "type": "ESTIMATED"
            },
            "lastUpdateSubmitDate": "2021-01-21",
            "lastUpdatePostDateStruct": {
                "date": "2021-01-25",
                "type": "ACTUAL"
            }
        },
        "sponsorCollaboratorsModule": {
            "responsibleParty": {
                "type": "SPONSOR"
            },
            "leadSponsor": {
                "name": "Pfizer's Upjohn has merged with Mylan to form Viatris Inc.",
                "class": "INDUSTRY"
            }
        },
        "oversightModule": {
            "oversightHasDmc": true
        },
        "descriptionModule": {
            "briefSummary": "This study, will compare pregabalin with placebo for the duration of 15 weeks to evaluate the efficacy and safety of pregabalin in patients with fibromyalgia."
        },
        "conditionsModule": {
            "conditions": [
                "Fibromyalgia"
            ]
        },
        "designModule": {
            "studyType": "INTERVENTIONAL",
            "phases": [
                "PHASE3"
            ],
            "designInfo": {
                "allocation": "RANDOMIZED",
                "interventionModel": "PARALLEL",
                "primaryPurpose": "TREATMENT",
                "maskingInfo": {
                    "masking": "TRIPLE",
                    "whoMasked": [
                        "PARTICIPANT",
                        "CARE_PROVIDER",
                        "INVESTIGATOR"
                    ]
                }
            },
            "enrollmentInfo": {
                "count": 498,
                "type": "ACTUAL"
            }
        },
        "armsInterventionsModule": {
            "armGroups": [
                {
                    "label": "Placebo",
                    "type": "PLACEBO_COMPARATOR",
                    "interventionNames": [
                        "Drug: Placebo"
                    ]
                },
                {
                    "label": "Pregabalin",
                    "type": "EXPERIMENTAL",
                    "interventionNames": [
                        "Drug: Pregabalin"
                    ]
                }
            ],
            "interventions": [
                {
                    "type": "DRUG",
                    "name": "Placebo",
                    "description": "Dosage: placebo, oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)",
                    "armGroupLabels": [
                        "Placebo"
                    ]
                },
                {
                    "type": "DRUG",
                    "name": "Pregabalin",
                    "description": "Dosage: 300 or 450 mg/day (150 or 225 mg bid), oral administration, Treatment duration: 15 weeks (3-week titration and 12-week fixed dose)",
                    "armGroupLabels": [
                        "Pregabalin"
                    ]
                }
            ]
        },
        "outcomesModule": {
            "primaryOutcomes": [
                {
                    "measure": "Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline",
                    "description": "Change from baseline in mean NRS-Pain scores at endpoint-LOCF. Daily pain scores were assessed on an 11-point numerical rating scale \\<(NRS)-Pain\\> ranging from 0 (no pain) to 10 (worst possible pain).",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                }
            ],
            "secondaryOutcomes": [
                {
                    "measure": "Percentage of Participants Who Was Categorized as \"Improved (Very Much Improved, Much Improved, or a Minimally Improved)\" According to the Patient Global Impressions of Change (PGIC)",
                    "description": "PGIC was defined as participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Change was defined as a score of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse) , 6 (much worse) or 7 (very much worse) on the scale.",
                    "timeFrame": "Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep disturbance. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of snoring. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of the symptom. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score indicates greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep adequacy. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of somnolence. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of overall sleep problems. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint",
                    "description": "MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Optimal sleep was defined as sleep quantity of 7 or 8 hours per night.",
                    "timeFrame": "Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Sleep Quality Score at Endpoint",
                    "description": "Change: Mean sleep quality score at endpoint minus mean at baseline. Sleep quality scores range from 0-10 with higher scores indicating decreased sleep quality.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety",
                    "description": "Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression",
                    "description": "Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                },
                {
                    "measure": "Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint",
                    "description": "The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.",
                    "timeFrame": "Baseline, Week 15 or study discontinuation"
                }
            ]
        },
        "eligibilityModule": {
            "eligibilityCriteria": "Inclusion Criteria:\n\n* ACR criteria for fibromyalgia\n* A score of more or equal to 40 mm on the Pain VAS\n* An average score more or equal to 4 on 4 daily pain diaries\n\nExclusion Criteria:\n\n* Patients with other severe pain conditions\n* Patients with severe depression\n* Patients taking excluded medications\n* Patients with suicidality",
            "healthyVolunteers": false,
            "sex": "ALL",
            "minimumAge": "18 Years",
            "stdAges": [
                "ADULT",
                "OLDER_ADULT"
            ]
        },
        "contactsLocationsModule": {
            "overallOfficials": [
                {
                    "name": "Pfizer CT.gov Call Center",
                    "affiliation": "Pfizer",
                    "role": "STUDY_DIRECTOR"
                }
            ],
            "locations": [
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Nagoya",
                    "state": "Aichi-ken",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.18147,
                        "lon": 136.90641
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Ichihara-shi",
                    "state": "Chiba",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Yotukaidou",
                    "state": "Chiba",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Matuyama-si",
                    "state": "Ehime",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Fukuoka",
                    "state": "Fukuoka",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 33.6,
                        "lon": 130.41667
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Iiduka",
                    "state": "Fukuoka",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Kitakyushu",
                    "state": "Fukuoka",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 33.85181,
                        "lon": 130.85034
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Takasaki",
                    "state": "Gunma",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 36.33333,
                        "lon": 139.01667
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Sapporo",
                    "state": "Hokkaido",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 43.06667,
                        "lon": 141.35
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Kobe",
                    "state": "Hyōgo",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.6913,
                        "lon": 135.183
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Mito",
                    "state": "Ibaraki",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 36.35,
                        "lon": 140.45
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Morioka",
                    "state": "Iwate",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 39.7,
                        "lon": 141.15
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Sagamihara-shi",
                    "state": "Kanagawa",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Yokohama",
                    "state": "Kanagawa",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.43333,
                        "lon": 139.65
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Koushi",
                    "state": "Kumamoto",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Tsu",
                    "state": "Mie-ken",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.73333,
                        "lon": 136.51667
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Sendai",
                    "state": "Miyagi",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 38.26667,
                        "lon": 140.86667
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Hiki-gun",
                    "state": "Saitama",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Saitama",
                    "state": "Saitama",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.90807,
                        "lon": 139.65657
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Saitama-shi",
                    "state": "Saitama",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Aoi-ku",
                    "state": "Shizuoka",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Shimotsuga-gun",
                    "state": "Tochigi",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Bunkyo-ku",
                    "state": "Tokyo",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Chiyoda-ku",
                    "state": "Tokyo",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Chuou-Ku",
                    "state": "Tokyo",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Itabashi-Ku",
                    "state": "Tokyo",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Setagaya City",
                    "state": "Tokyo",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.64188,
                        "lon": 139.64715
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Setagaya-ku",
                    "state": "Tokyo",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Shinagawa-Ku",
                    "state": "Tokyo",
                    "country": "Japan"
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Toyama",
                    "state": "Toyama",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 36.7,
                        "lon": 137.21667
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Nagano",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 36.65,
                        "lon": 138.18333
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Osaka",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.69379,
                        "lon": 135.50107
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Ōita",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 33.23333,
                        "lon": 131.6
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Tokushima",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 34.06667,
                        "lon": 134.56667
                    }
                },
                {
                    "facility": "Pfizer Investigational Site",
                    "city": "Yokohama",
                    "country": "Japan",
                    "geoPoint": {
                        "lat": 35.43333,
                        "lon": 139.65
                    }
                }
            ]
        },
        "referencesModule": {
            "references": [
                {
                    "pmid": "26694975",
                    "type": "DERIVED",
                    "citation": "Clair A, Emir B. The safety and efficacy of pregabalin for treating subjects with fibromyalgia and moderate or severe baseline widespread pain. Curr Med Res Opin. 2016;32(3):601-9. doi: 10.1185/03007995.2015.1134463. Epub 2016 Jan 27."
                },
                {
                    "pmid": "23062189",
                    "type": "DERIVED",
                    "citation": "Ohta H, Oka H, Usui C, Ohkura M, Suzuki M, Nishioka K. A randomized, double-blind, multicenter, placebo-controlled phase III trial to evaluate the efficacy and safety of pregabalin in Japanese patients with fibromyalgia. Arthritis Res Ther. 2012 Oct 12;14(5):R217. doi: 10.1186/ar4056."
                }
            ],
            "seeAlsoLinks": [
                {
                    "label": "To obtain contact information for a study center near you, click here.",
                    "url": "https://trialinfoemail.pfizer.com/pages/landing.aspx?StudyID=A0081208&StudyName=Randomized%2C%20Double-Blind%2C%20Placebo-Controlled%20Study%20Of%20Pregabalin%20In%20Patients%20With%20Fibromyalgia"
                }
            ]
        }
    },
    "resultsSection": {
        "participantFlowModule": {
            "preAssignmentDetails": "Participants were administered placebo tablet in single blind manner and evaluated for the inclusion/exclusion criteria during the 1-week screening phase. Participants who demonstrated a high response to placebo, i.e., \\<=30% decrease on the VAS, were discontinued from the study at the end of the screening phase.",
            "groups": [
                {
                    "id": "FG000",
                    "title": "Placebo",
                    "description": "Placebo was administered twice a day for 15 weeks."
                },
                {
                    "id": "FG001",
                    "title": "Pregabalin",
                    "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                }
            ],
            "periods": [
                {
                    "title": "Overall Study",
                    "milestones": [
                        {
                            "type": "STARTED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "comment": "Treated",
                                    "numSubjects": "248"
                                },
                                {
                                    "groupId": "FG001",
                                    "comment": "Treated",
                                    "numSubjects": "250"
                                }
                            ]
                        },
                        {
                            "type": "COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "208"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "207"
                                }
                            ]
                        },
                        {
                            "type": "NOT COMPLETED",
                            "achievements": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "40"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "43"
                                }
                            ]
                        }
                    ],
                    "dropWithdraws": [
                        {
                            "type": "Lack of Efficacy",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "26"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "10"
                                }
                            ]
                        },
                        {
                            "type": "Adverse Event",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "8"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "24"
                                }
                            ]
                        },
                        {
                            "type": "Not meeting entrance criteria",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "5"
                                }
                            ]
                        },
                        {
                            "type": "Withdrawal by Subject",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "0"
                                }
                            ]
                        },
                        {
                            "type": "Lost to Follow-up",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Protocol Violation",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "0"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "1"
                                }
                            ]
                        },
                        {
                            "type": "Other",
                            "reasons": [
                                {
                                    "groupId": "FG000",
                                    "numSubjects": "2"
                                },
                                {
                                    "groupId": "FG001",
                                    "numSubjects": "2"
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "baselineCharacteristicsModule": {
            "groups": [
                {
                    "id": "BG000",
                    "title": "Placebo",
                    "description": "Placebo was administered twice a day for 15 weeks."
                },
                {
                    "id": "BG001",
                    "title": "Pregabalin",
                    "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                },
                {
                    "id": "BG002",
                    "title": "Total",
                    "description": "Total of all reporting groups"
                }
            ],
            "denoms": [
                {
                    "units": "Participants",
                    "counts": [
                        {
                            "groupId": "BG000",
                            "value": "248"
                        },
                        {
                            "groupId": "BG001",
                            "value": "250"
                        },
                        {
                            "groupId": "BG002",
                            "value": "498"
                        }
                    ]
                }
            ],
            "measures": [
                {
                    "title": "Age, Customized",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "title": "<18 years",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "0"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "0"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Between 18 years and 44 years",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "104"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "101"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "205"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": "Between 45 years and 64 years",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "123"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "125"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "248"
                                        }
                                    ]
                                }
                            ]
                        },
                        {
                            "title": ">=65 years",
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "21"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "24"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "45"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                },
                {
                    "title": "Sex: Female, Male",
                    "paramType": "COUNT_OF_PARTICIPANTS",
                    "unitOfMeasure": "Participants",
                    "classes": [
                        {
                            "categories": [
                                {
                                    "title": "Female",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "217"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "226"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "443"
                                        }
                                    ]
                                },
                                {
                                    "title": "Male",
                                    "measurements": [
                                        {
                                            "groupId": "BG000",
                                            "value": "31"
                                        },
                                        {
                                            "groupId": "BG001",
                                            "value": "24"
                                        },
                                        {
                                            "groupId": "BG002",
                                            "value": "55"
                                        }
                                    ]
                                }
                            ]
                        }
                    ]
                }
            ]
        },
        "outcomeMeasuresModule": {
            "outcomeMeasures": [
                {
                    "type": "PRIMARY",
                    "title": "Change From Baseline for Numerical Rating Scale (NRS) Pain Scores at Endpoint-LOCF (Last Observation Carried Forward) Relative to Baseline",
                    "description": "Change from baseline in mean NRS-Pain scores at endpoint-LOCF. Daily pain scores were assessed on an 11-point numerical rating scale \\<(NRS)-Pain\\> ranging from 0 (no pain) to 10 (worst possible pain).",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.03",
                                            "spread": "0.12"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.48",
                                            "spread": "0.12"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0046",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025. Actual significance level was calculated based on O'Brien-Fleming type alpha spending function of Lan and DeMets (1983).",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.44",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.78",
                            "ciUpperLimit": "-0.11",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.17"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Percentage of Participants Who Was Categorized as \"Improved (Very Much Improved, Much Improved, or a Minimally Improved)\" According to the Patient Global Impressions of Change (PGIC)",
                    "description": "PGIC was defined as participant rated instrument to measure participant's change in overall status on a 7-point scale; range from 1 (very much improved) to 7 (very much worse). Change was defined as a score of 1 (very much improved), 2 (much improved), 3 (minimally improved), 4 (no change), 5 (minimally worse) , 6 (much worse) or 7 (very much worse) on the scale.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Percentage of participants",
                    "timeFrame": "Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "62.1"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "70.0"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that there was a difference between the pregabalin and the placebo groups.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0078",
                            "pValueComment": "The analysis was conducted using 2-sided test with the significance level of 0.05.",
                            "statisticalMethod": "Chi-squared",
                            "ciNumSides": "TWO_SIDED"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Disturbance",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Disturbance subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep disturbance. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-8.13",
                                            "spread": "1.31"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-17.62",
                                            "spread": "1.31"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "<0.0001",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-9.48",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-13.12",
                            "ciUpperLimit": "-5.85",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.85"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Snoring",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Snoring subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of snoring. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.61",
                                            "spread": "1.33"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3.37",
                                            "spread": "1.33"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.9958",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "4.98",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "1.29",
                            "ciUpperLimit": "8.68",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.88"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Awaken Short of Breath or With a Headache",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Awaken Short of Breath or With a Headache subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of the symptom. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-3.02",
                                            "spread": "1.36"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-8.01",
                                            "spread": "1.36"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0049",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-4.99",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-8.77",
                            "ciUpperLimit": "-1.21",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.92"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Quantity of Sleep",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Quantity of Sleep subscales rated 0 to 24 (number of hours slept). A higher score indicates greater quantity of sleep. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.17",
                                            "spread": "0.06"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "0.46",
                                            "spread": "0.06"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0007",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "0.29",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.11",
                            "ciUpperLimit": "0.47",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.09"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Sleep Adequacy",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Sleep Adequacy subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of sleep adequacy. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8.02",
                                            "spread": "1.41"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "15.50",
                                            "spread": "1.40"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "<0.0001",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "7.48",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "3.58",
                            "ciUpperLimit": "11.38",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.99"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Somnolence",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Somnolence subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of somnolence. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-4.66",
                                            "spread": "1.29"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "6.65",
                                            "spread": "1.28"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "1.0000",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "11.31",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "7.74",
                            "ciUpperLimit": "14.87",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.82"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Medical Outcomes Study (MOS) Sleep Scale at Endpoint- Overall Sleep Problems Index",
                    "description": "MOS: participant-rated questionnaire to assess sleep quality and quantity. Consists of 9-item overall sleep problems index (length of time to fall asleep, how many hours of sleep each night during past 4 weeks); The MOS Overall Sleep Problems Index subscales rated 1 (all the time) to 6 (none of the time). Scores are transformed (actual raw score minus lowest possible score) divided by possible raw score range multiplied by 100; total score range = 0 to 100. A higher score indicates greater intensity of overall sleep problems. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-7.07",
                                            "spread": "0.96"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-10.06",
                                            "spread": "0.95"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0137",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-2.99",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-5.65",
                            "ciUpperLimit": "-0.33",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.35"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Medical Outcomes Study (MOS) Sleep Scale - Number of Participants With Optimal Sleep at Endpoint",
                    "description": "MOS-Sleep is a patient-rated questionnaire to assess sleep quality and quantity. Optimal sleep component is derived from Sleep Quantity average hours of sleep each night during the past 4 weeks. Optimal sleep was defined as sleep quantity of 7 or 8 hours per night.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "NUMBER",
                    "unitOfMeasure": "Participants",
                    "timeFrame": "Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "53"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "71"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0687",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "Regression, Logistic",
                            "paramType": "Odds Ratio (OR)",
                            "paramValue": "1.45",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "0.90",
                            "ciUpperLimit": "2.35"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Sleep Quality Score at Endpoint",
                    "description": "Change: Mean sleep quality score at endpoint minus mean at baseline. Sleep quality scores range from 0-10 with higher scores indicating decreased sleep quality.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.79",
                                            "spread": "0.12"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.52",
                                            "spread": "0.12"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "<0.0001",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.73",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.06",
                            "ciUpperLimit": "-0.40",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.17"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Total Scores",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-7.26",
                                            "spread": "1.08"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-10.59",
                                            "spread": "1.07"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0144",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-3.33",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-6.31",
                            "ciUpperLimit": "-0.35",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.52"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Physical Function",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.19",
                                            "spread": "0.11"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.47",
                                            "spread": "0.11"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0376",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.28",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.59",
                            "ciUpperLimit": "0.03",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.16"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Feel Good",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.82",
                                            "spread": "0.17"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.45",
                                            "spread": "0.17"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0052",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.63",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.12",
                            "ciUpperLimit": "-0.15",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.25"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Work Miss",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.30",
                                            "spread": "0.15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.31",
                                            "spread": "0.15"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.4768",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.01",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.42",
                            "ciUpperLimit": "0.40",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.21"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Housework",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.00",
                                            "spread": "0.15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.32",
                                            "spread": "0.15"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0729",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.31",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.74",
                            "ciUpperLimit": "0.11",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.21"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Pain",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-1.06",
                                            "spread": "0.15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.46",
                                            "spread": "0.15"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0238",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.41",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.81",
                            "ciUpperLimit": "0.00",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.21"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Tiredness",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.94",
                                            "spread": "0.14"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.43",
                                            "spread": "0.14"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0075",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.49",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.89",
                            "ciUpperLimit": "-0.10",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.20"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Morning",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.97",
                                            "spread": "0.15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.56",
                                            "spread": "0.15"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0023",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.59",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.01",
                            "ciUpperLimit": "-0.18",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.21"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Stiffness",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.90",
                                            "spread": "0.15"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-1.05",
                                            "spread": "0.15"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.2568",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.14",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.57",
                            "ciUpperLimit": "0.29",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.22"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Anxious",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.64",
                                            "spread": "0.16"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.92",
                                            "spread": "0.16"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.1011",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.28",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.72",
                            "ciUpperLimit": "0.15",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.22"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Fibromyalgia Impact Questionnaire (FIQ) at Endpoint - Depression",
                    "description": "FIQ is a 20-item patient-reported outcome instrument designed to assess health status, progress, and outcomes in patients with fibromyalgia (10 subscales; 11 questions). Scores range from 0 to 100 with higher scores indicating more impairment. Change = mean FIQ scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.51",
                                            "spread": "0.14"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.55",
                                            "spread": "0.14"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.4165",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.04",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.44",
                            "ciUpperLimit": "0.35",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.20"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Physical Functioning",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "4.72",
                                            "spread": "0.93"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "9.01",
                                            "spread": "0.93"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0006",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "4.29",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "1.70",
                            "ciUpperLimit": "6.88",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.32"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Physical",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "8.36",
                                            "spread": "1.30"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "10.04",
                                            "spread": "1.30"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.1805",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "1.68",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-1.93",
                            "ciUpperLimit": "5.29",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.84"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Bodily Pain",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "9.50",
                                            "spread": "1.06"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "11.65",
                                            "spread": "1.06"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0770",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "2.15",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.81",
                            "ciUpperLimit": "5.10",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.50"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- General Health Perception",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "2.83",
                                            "spread": "0.85"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "4.66",
                                            "spread": "0.85"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0648",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "1.83",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.54",
                            "ciUpperLimit": "4.19",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.20"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Social Functioning",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "6.84",
                                            "spread": "1.38"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "8.43",
                                            "spread": "1.37"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.2068",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "1.59",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-2.23",
                            "ciUpperLimit": "5.41",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.94"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Role Limitations-Emotional",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.50",
                                            "spread": "1.36"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "3.27",
                                            "spread": "1.35"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.5480",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.23",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-4.00",
                            "ciUpperLimit": "3.54",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.92"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Vitality",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "5.12",
                                            "spread": "1.22"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "9.53",
                                            "spread": "1.21"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0052",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "4.42",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "1.04",
                            "ciUpperLimit": "7.80",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.72"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Analysis of SF-36 Health Survey Results at Endpoint- Mental Health",
                    "description": "Subject-rated measure of health status comprised of 36 items: 8 subscale scores (physical functioning, role limitations-physical, bodily pain, general health perceptions, vitality, social functioning, role limitations-emotional, and mental health. Subscale scores range: 0-100. Higher subscale scores = better health status. Change from baseline = score at observation minus score at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "3.33",
                                            "spread": "0.98"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "5.97",
                                            "spread": "0.98"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0287",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "2.64",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.08",
                            "ciUpperLimit": "5.37",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "1.39"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Anxiety",
                    "description": "Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-0.09",
                                            "spread": "0.18"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.57",
                                            "spread": "0.18"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0262",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.48",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.97",
                            "ciUpperLimit": "0.01",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.25"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Hospital Anxiety and Depression Scale (HADS) - Depression",
                    "description": "Change: Mean HADS score at observation minus Mean at baseline. HADS anxiety and depression subscale scores range from 0 to 21, with higher scores indicating greater severity of the subscale condition.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "247"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "249"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "0.00",
                                            "spread": "0.20"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-0.29",
                                            "spread": "0.20"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.1561",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-0.28",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-0.83",
                            "ciUpperLimit": "0.27",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "0.28"
                        }
                    ]
                },
                {
                    "type": "SECONDARY",
                    "title": "Change From Baseline in Pain Visual Analog Scale (Pain VAS) Score at Endpoint",
                    "description": "The pain VAS is a horizontal line; 100 mm in length, self-administered by the patient to rate pain from 0 (no pain) to 100 (worst possible pain). The score indicates the pain intensity during the past 1 week before a visit. Change = mean scores at observation minus mean scores at baseline.",
                    "populationDescription": "The full analysis set (FAS) consisted of all randomized participants who received at least 1 dose of study medication and had at least 1 postbaseline pain score on study medication. Last observation carried forward (LOCF) method was used.",
                    "reportingStatus": "POSTED",
                    "paramType": "LEAST_SQUARES_MEAN",
                    "dispersionType": "Standard Error",
                    "unitOfMeasure": "Scores on a scale",
                    "timeFrame": "Baseline, Week 15 or study discontinuation",
                    "groups": [
                        {
                            "id": "OG000",
                            "title": "Placebo",
                            "description": "Placebo was administered twice a day for 15 weeks."
                        },
                        {
                            "id": "OG001",
                            "title": "Pregabalin",
                            "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase."
                        }
                    ],
                    "denoms": [
                        {
                            "units": "Participants",
                            "counts": [
                                {
                                    "groupId": "OG000",
                                    "value": "248"
                                },
                                {
                                    "groupId": "OG001",
                                    "value": "250"
                                }
                            ]
                        }
                    ],
                    "classes": [
                        {
                            "categories": [
                                {
                                    "measurements": [
                                        {
                                            "groupId": "OG000",
                                            "value": "-14.11",
                                            "spread": "1.45"
                                        },
                                        {
                                            "groupId": "OG001",
                                            "value": "-20.30",
                                            "spread": "1.44"
                                        }
                                    ]
                                }
                            ]
                        }
                    ],
                    "analyses": [
                        {
                            "groupIds": [
                                "OG000",
                                "OG001"
                            ],
                            "groupDescription": "The null hypothesis was to assume that there was no difference between the pregabalin and placebo groups. The alternative was that the pregabalin group was superior to the placebo group.",
                            "nonInferiorityType": "SUPERIORITY_OR_OTHER_LEGACY",
                            "pValue": "0.0013",
                            "pValueComment": "The analysis was conducted using 1-sided test with the significance level of 0.025.",
                            "statisticalMethod": "ANCOVA",
                            "paramType": "Mean Difference (Final Values)",
                            "paramValue": "-6.19",
                            "ciPctValue": "95",
                            "ciNumSides": "TWO_SIDED",
                            "ciLowerLimit": "-10.20",
                            "ciUpperLimit": "-2.18",
                            "dispersionType": "STANDARD_ERROR_OF_MEAN",
                            "dispersionValue": "2.04"
                        }
                    ]
                }
            ]
        },
        "adverseEventsModule": {
            "frequencyThreshold": "5",
            "description": "The same event may appear as both an AE and a SAE. However, what is presented are distinct events. An event may be categorized as serious in one subject and as nonserious in another subject, or one subject may have experienced both a serious and nonserious event during the study.",
            "eventGroups": [
                {
                    "id": "EG000",
                    "title": "Placebo",
                    "description": "Placebo was administered twice a day for 15 weeks.",
                    "seriousNumAffected": 0,
                    "seriousNumAtRisk": 248,
                    "otherNumAffected": 113,
                    "otherNumAtRisk": 248
                },
                {
                    "id": "EG001",
                    "title": "Pregabalin",
                    "description": "Pregabalin was administered twice a day at the starting dose of 150 mg/day in the first week and escalated to 300 mg/day at the end of Week 1. Pregabalin dose was titrated to 450 mg/day at the end of Week 2 based on the participant's individual response and tolerability to pregabalin. Treatment period was 15 weeks that consisted of 3-week dose optimization phase and 12-week fixed dose phase.",
                    "seriousNumAffected": 1,
                    "seriousNumAtRisk": 250,
                    "otherNumAffected": 195,
                    "otherNumAtRisk": 250
                }
            ],
            "seriousEvents": [
                {
                    "term": "Breast cancer",
                    "organSystem": "Neoplasms benign, malignant and unspecified (incl cysts and polyps)",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 0,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 1,
                            "numAtRisk": 250
                        }
                    ]
                }
            ],
            "otherEvents": [
                {
                    "term": "Vision blurred",
                    "organSystem": "Eye disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 13,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Constipation",
                    "organSystem": "Gastrointestinal disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 17,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 36,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Feeling abnormal",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 20,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Oedema peripheral",
                    "organSystem": "General disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 3,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 18,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Nasopharyngitis",
                    "organSystem": "Infections and infestations",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 45,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 45,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Weight increased",
                    "organSystem": "Investigations",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 9,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 39,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Dizziness",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 15,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 74,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Headache",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 15,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 15,
                            "numAtRisk": 250
                        }
                    ]
                },
                {
                    "term": "Somnolence",
                    "organSystem": "Nervous system disorders",
                    "sourceVocabulary": "MedDRA 14.0",
                    "assessmentType": "SYSTEMATIC_ASSESSMENT",
                    "stats": [
                        {
                            "groupId": "EG000",
                            "numAffected": 45,
                            "numAtRisk": 248
                        },
                        {
                            "groupId": "EG001",
                            "numAffected": 116,
                            "numAtRisk": 250
                        }
                    ]
                }
            ]
        },
        "moreInfoModule": {
            "certainAgreement": {
                "piSponsorEmployee": false,
                "restrictionType": "OTHER",
                "restrictiveAgreement": true,
                "otherDetails": "Pfizer has the right to review disclosures, requesting a delay of less than 60 days. Investigator will postpone single center publications until after disclosure of pooled data (all sites), less than 12 months from study completion/termination at all participating sites. Investigator may not disclose previously undisclosed confidential information other than study results."
            },
            "pointOfContact": {
                "title": "Pfizer ClinicalTrials.gov Call Center",
                "organization": "Pfizer, Inc.",
                "email": "ClinicalTrials.gov_Inquiries@pfizer.com",
                "phone": "1-800-718-1021"
            }
        }
    },
    "derivedSection": {
        "miscInfoModule": {
            "versionHolder": "2025-12-29"
        },
        "conditionBrowseModule": {
            "meshes": [
                {
                    "id": "D005356",
                    "term": "Fibromyalgia"
                }
            ],
            "ancestors": [
                {
                    "id": "D009135",
                    "term": "Muscular Diseases"
                },
                {
                    "id": "D009140",
                    "term": "Musculoskeletal Diseases"
                },
                {
                    "id": "D012216",
                    "term": "Rheumatic Diseases"
                },
                {
                    "id": "D009468",
                    "term": "Neuromuscular Diseases"
                },
                {
                    "id": "D009422",
                    "term": "Nervous System Diseases"
                }
            ]
        },
        "interventionBrowseModule": {
            "meshes": [
                {
                    "id": "D000069583",
                    "term": "Pregabalin"
                }
            ],
            "ancestors": [
                {
                    "id": "D005680",
                    "term": "gamma-Aminobutyric Acid"
                },
                {
                    "id": "D000613",
                    "term": "Aminobutyrates"
                },
                {
                    "id": "D002087",
                    "term": "Butyrates"
                },
                {
                    "id": "D000144",
                    "term": "Acids, Acyclic"
                },
                {
                    "id": "D002264",
                    "term": "Carboxylic Acids"
                },
                {
                    "id": "D009930",
                    "term": "Organic Chemicals"
                },
                {
                    "id": "D000596",
                    "term": "Amino Acids"
                },
                {
                    "id": "D000602",
                    "term": "Amino Acids, Peptides, and Proteins"
                }
            ]
        }
    },
    "hasResults": true
}